Therapeutic Malonic Acid/Acetic Acid C60 Tri-Adducts of Buckminsterfullerene and Methods Related Thereto

Abstract

Disclosed and claimed herein are e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene of the general formula C 60 R 3 , wherein each R is independently selected from groups of the formula —CR 1 R 2 wherein each R 1 and R 2 is independently selected from the group consisting of —H and —COOH, provided, however, that at least one of the R 1 's and R 2 's is a hydrogen. Processes for preparing and uses of the same for treating neuronal injury and for life-extension are also disclosed and claimed herein.

1 .- 21 . (canceled) 
     
     
         22 . A process for extending the lifespan of a mammalian cell comprising administering to a mammal a composition comprising an e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene of the formula C 60 (R) 3  represented by the following structure: 
       
         
           
           
               
               
           
         
       
       wherein each R is independently selected from the group consisting of moieties of the formula ═CR 1 R 2 , wherein each R 1  and R 2  of said ═CR 1 R 2  moiety is independently selected from the group consisting of —H and —COOH, provided, however, that at least one R 1  or R 2  of at least one of said ═CR 1 R 2  moieties is a hydrogen, and wherein the C in each of said ═CR 1 R 2  moieties is bonded directly to two adjacent carbons of the C 60  moiety. 
     
     
         23 . The process of  claim 22  wherein said e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene is selected from the group consisting of C 60 (C(COOH) 2 ) 2 (CHCOOH), C 60 (C(COOH) 2 )(CHCOOH) 2 , and C 60 (CHCOOH 3 . 
     
     
         24 . The process of  claim 22  wherein said composition comprises said e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene, its pharmaceutically acceptable salts and pharmaceutically accepted esters, and a pharmaceutically acceptable carrier, present in said composition in a therapeutically effective amount. 
     
     
         25 . The process of  claim 24  wherein said e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene is administered intravenously, intramuscularly, subcutaneously or orally. 
     
     
         26 . The process of  claim 25  wherein said e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene is administered intravenously, intramuscularly or subcutaneously in an amount of at least 0.1 mg/kg. 
     
     
         27 . The process of  claim 26  wherein said e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene is administered intravenously, intramuscularly or subcutaneously in an amount of about 3 mg/kg. 
     
     
         28 . The process of  claim 25  wherein said e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene is administered orally in an amount of at least 0.1 mg/kg. 
     
     
         29 . The process of  claim 25  wherein said e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene is administered orally in an amount of about 15 mg/kg. 
     
     
         30 . The process of  claim 25  wherein said e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene is administered daily. 
     
     
         31 . (canceled) 
     
     
         32 . The process of claim  1  wherein said mammal is a human. 
     
     
         33 . The process of claim  1  wherein said mammal is a companion animal. 
     
     
         34 .- 69 . (canceled)